Clinically Media at AD/PD 2026: Advancing CNS Research Together
Clinically Media at AD/PD 2026: Advancing CNS Research Together
Clinically Media is excited to be attending the Alzheimer’s & Parkinson’s Diseases Conference (AD/PD™) this year, one of the leading global meetings focused on neurodegenerative research and therapeutic development. The meeting will be held March 17-21, 2026 in Copenhagen, Denmark.
This year, Myra Zerr-Korolev will be representing both the Clinically Media and LyfeSci teams at the conference, and we are thrilled to have her there connecting with the CNS research community.
Why AD/PD Matters
The AD/PD conference brings together scientists, clinicians, biotech companies, and clinical research organizations working to advance treatments for Alzheimer’s disease, Parkinson’s disease, and related neurological disorders.
The meeting serves as an important platform for:
Sharing new discoveries in neurodegenerative disease research
Discussing clinical development strategies and emerging therapies
Building collaborations that help move promising science into clinical trials
For Clinically Media, attending AD/PD reflects our ongoing commitment to supporting CNS-focused clinical research through specialized patient recruitment strategies and patient-centered engagement.
Representing Clinically Media and LyfeSci: Myra Zerr-Korolev
We are especially excited to have Myra Zerr-Korolev attending AD/PD on behalf of both Clinically Media and LyfeSci.
Myra brings a strong background in patient recruitment combined with experience working within neuroscience research environments, giving her a unique perspective on the complexities of CNS clinical trials. Recruiting for neurological studies often requires thoughtful strategies that account for caregiver involvement, diagnostic complexity, and specialized patient populations.
Her expertise allows her to effectively bridge the operational and scientific sides of clinical research, making her a fantastic representative for our teams at this conference.
Expanding CNS Capabilities Through LyfeSci
This year’s AD/PD conference is particularly exciting for us following the recent acquisition of Clinically Media by LyfeSci Research & Innovation.
The acquisition expands LyfeSci’s ability to deliver patient-centric clinical development capabilities, strengthening recruitment and engagement strategies for sponsors running complex clinical trials.
You can read the full announcement here:
https://www.businesswire.com/news/home/20260109474518/en/LyfeSci-Research-Innovation-Acquires-Clinically-Media-to-Expand-Patient-Centric-Clinical-Trial-Capabilities
LyfeSci’s CEO and Founder, Tapan Parikh, MD, MPH, MBA will also be attending AD/PD.
As a psychiatrist and experienced clinical research leader, Dr. Parikh brings a deep understanding of CNS therapeutic development. His experience is particularly valuable for early-stage biotech companies, helping them navigate scientific strategy, trial design, and development pathways as they move new therapies into clinical testing.
Together, LyfeSci and Clinically Media are building a more integrated approach to supporting CNS clinical trials—from early development strategy through patient recruitment and trial execution.
Our Experience Supporting CNS Clinical Trials
Clinically Media has extensive experience supporting patient recruitment for CNS studies across multiple neurological indications.
Recent examples include:
Supporting Alzheimer’s enrollment efforts for potential treatments
Supporting migraine enrollment efforts for potential treatments
Supporting the Neuraly PRISM study for early-stage Parkinson’s disease
These projects demonstrate our ability to identify and engage the right patient populations, develop tailored outreach strategies, and support enrollment for complex neurological research studies.
Let’s Connect at AD/PD
If you will be attending AD/PD this year, we would love to connect.
We are especially interested in meeting with companies at all stages of research and development, including early-stage organizations developing innovative CNS therapies.
If you’re planning to attend, let Myra know you’ll be there! We’d be excited to set up time to meet during the conference.
We look forward to being part of the conversations shaping the future of Alzheimer’s, Parkinson’s, and broader CNS research.
